Brain Tumor Drug Delivery System Development

The incidence of brain tumors is increasing year by year, but the treatment outcome has not improved significantly. The treatment of brain tumors remains a worldwide challenge. The reason for this is the complexity and specificity of their growth and development. Compared with peripheral tumors, the physiological and pathological environment of brain tumors is significantly different. In addition, the delivery of drugs into the brain has been another major challenge in the treatment of brain tumors due to the limitations of the blood-brain barrier (BBB).

Figure 1. Structure of BBB tight junctions. (Abbott, N. J., et al., 2010)

We offer services for the development of bacteria-based drug delivery systems for brain tumors

The BBB is a dynamic interface that limits and controls the passage of substances between the peripheral vascular circulation and the central nervous system (CNS). It prevents the entry of neurotoxic plasma components, blood cells, and pathogens into the brain, thus protecting the CNS from harmful substances or excessive immune responses.

However, this complex interface, while protecting the brain from harmful chemicals or toxins that may be present in the systemic circulation, also results in the inability of therapeutic agents to cross the blood-brain barrier. In response to this urgent need and significant challenge, Alfa Cytology has taken a major step forward in the development of a drug delivery system for brain tumors. We offer our customers four development options, nanoparticle-based, microchip-based, bacterial-based, and exosome-based.

We explore the possible routes of drug delivery across the blood-brain barrier to the brain tumor lesion site in several ways. We design targeted drug delivery systems applicable to different physiological and pathological characteristics according to the pattern of brain tumor occurrence and progression. We aim to deliver the right amount of drugs to the right location at the right time. This increases the efficiency of drug utilization, effectively improves the targeting and therapeutic effect of brain tumors, and reduces toxic side effects.

Our general approach to brain tumor drug delivery system development process

Note: The above is a generic process only. Each development program we offer for different pathological characteristics and needs is somewhat different to emphasize its good targeting. Please consult our staff for details.

Advantages of our services

Alfa Cytology provides development services for targeted drug delivery systems for different physiological and pathological characteristics and needs of brain tumors. The drug delivery systems we develop have the advantages of high anti-brain tumor efficacy, low toxic side effects, high maximum tolerated dose, and high targeting. We have been focusing on all aspects of brain tumor research. If you are interested in our services or have any interest in working with us, please feel free to contact us. We look forward to working with you in the development of drug delivery systems for brain tumors.

Reference

1. Abbott, N. J., et al. (2010). "Structure and function of the blood–brain barrier." Neurobiology of Disease, 37(1), 13-25.